IPO registrations (S-1, F-1) · Registrants
Aditxt, Inc.
- SEC CIK
- 1726711 · filings on EDGAR ↗
- Former names
- ADiTx Therapeutics, Inc. (2020–2021); Aditx Therapeutics, Inc. (2020–2021)
- Registration
- Form S-1, first filed 2020-01-15, last 2025-06-20; 9 initial registrations, 16 amendments
- Outcome
- Final prospectus filed 2020-07-01; declared effective 2020-06-29; withdrawal requested 2023-09-22
- Industry (SIC)
- Pharmaceutical Preparations 2834
- Incorporated in
- DE
- Business address
- 737 N. FIFTH STREET, SUITE 200, Richmond, VA 23219
- EIN
- 82-3204328
- EDGAR entity type
- operating
- Insiders and CEO pay
- Aditxt, Inc. on the corporate pages
Offering terms
- Final price
- $9.00 per share (424B4 filed 2020-07-01, an initial public offering)
- Shares sold
- 1,226,668
- Gross proceeds
- $11,040,012 before underwriting discounts and any over-allotment option
- Listing
- Nasdaq under the symbol ADTX
- Lead underwriters
- Dawson James (472,222 shares)
- Syndicate
- James Securities, Inc; ViewTrade (377,223); Securities, Inc; The Benchmark Company (377,223)
Read from the cover pages of the filings listed under “Prospectus pages read” below; check the document for anything that matters.
On this site
- Business registration: Aditxt, Inc. Fuzzy (name and state)
- Form D issuer: Aditxt, Inc. EXACT (CIK (EXACT))
- Lobbying client: ADITXT INC. Fuzzy (name and state)
- SEC filer: Aditx Therapeutics, Inc. EXACT (CIK (EXACT))
Filings 42
| Filed | Form | What it is | Name as filed | EDGAR |
|---|---|---|---|---|
| 2020-01-15 | S-1 | S-1 (registration) | ADiTx Therapeutics, Inc. | 0001213900-20-001135 ↗ |
| 2020-02-07 | S-1/A | S-1/A (amendment) | ADiTx Therapeutics, Inc. | 0001213900-20-002914 ↗ |
| 2020-02-19 | S-1/A | S-1/A (amendment) | ADiTx Therapeutics, Inc. | 0001213900-20-004282 ↗ |
| 2020-04-28 | S-1/A | S-1/A (amendment) | ADiTx Therapeutics, Inc. | 0001213900-20-010308 ↗ |
| 2020-05-14 | S-1/A | S-1/A (amendment) | ADiTx Therapeutics, Inc. | 0001213900-20-012077 ↗ |
| 2020-05-29 | S-1/A | S-1/A (amendment) | ADiTx Therapeutics, Inc. | 0001213900-20-013734 ↗ |
| 2020-06-17 | S-1/A | S-1/A (amendment) | ADiTx Therapeutics, Inc. | 0001213900-20-015193 ↗ |
| 2020-06-24 | S-1/A | S-1/A (amendment) | ADiTx Therapeutics, Inc. | 0001213900-20-015613 ↗ |
| 2020-06-25 | S-1/A | S-1/A (amendment) | ADiTx Therapeutics, Inc. | 0001213900-20-015750 ↗ |
| 2020-06-29 | EFFECT | EFFECT (declared effective) | ADiTx Therapeutics, Inc. | 9999999995-20-001668 ↗ |
| 2020-07-01 | 424B4 | 424B4 (final prospectus) | ADiTx Therapeutics, Inc. | 0001213900-20-016472 ↗ |
| 2020-08-28 | S-1 | S-1 (registration) | ADiTx Therapeutics, Inc. | 0001213900-20-024322 ↗ |
| 2020-09-01 | EFFECT | EFFECT (declared effective) | ADiTx Therapeutics, Inc. | 9999999995-20-002338 ↗ |
| 2020-09-02 | S-1MEF | S-1MEF (added securities) | ADiTx Therapeutics, Inc. | 0001213900-20-024908 ↗ |
| 2020-09-03 | 424B4 | 424B4 (final prospectus) | ADiTx Therapeutics, Inc. | 0001213900-20-025234 ↗ |
| 2021-02-04 | S-1 | S-1 (registration) | Aditx Therapeutics, Inc. | 0001213900-21-006626 ↗ |
| 2021-02-10 | EFFECT | EFFECT (declared effective) | Aditx Therapeutics, Inc. | 9999999995-21-000565 ↗ |
| 2021-07-13 | EFFECT | EFFECT (declared effective) | Aditxt, Inc. | 9999999995-21-002744 ↗ |
| 2022-07-18 | S-1 | S-1 (registration) | Aditxt, Inc. | 0001213900-22-039769 ↗ |
| 2022-09-15 | S-1/A | S-1/A (amendment) | Aditxt, Inc. | 0001213900-22-056026 ↗ |
| 2022-09-15 | S-1/A | S-1/A (amendment) | Aditxt, Inc. | 0001213900-22-056228 ↗ |
| 2022-09-16 | S-1/A | S-1/A (amendment) | Aditxt, Inc. | 0001213900-22-056371 ↗ |
| 2022-09-16 | EFFECT | EFFECT (declared effective) | Aditxt, Inc. | 9999999995-22-002729 ↗ |
| 2022-09-20 | 424B4 | 424B4 (final prospectus) | Aditxt, Inc. | 0001213900-22-057179 ↗ |
| 2023-06-29 | S-1 | S-1 (registration) | Aditxt, Inc. | 0001213900-23-052531 ↗ |
| 2023-09-15 | S-1 | S-1 (registration) | Aditxt, Inc. | 0001213900-23-077044 ↗ |
| 2023-09-21 | EFFECT | EFFECT (declared effective) | Aditxt, Inc. | 9999999995-23-002719 ↗ |
| 2023-09-22 | RW | RW (withdrawal request) | Aditxt, Inc. | 0001213900-23-078579 ↗ |
| 2023-11-07 | S-1 | S-1 (registration) | Aditxt, Inc. | 0001213900-23-084402 ↗ |
| 2023-11-13 | EFFECT | EFFECT (declared effective) | Aditxt, Inc. | 9999999995-23-003339 ↗ |
| 2024-01-18 | S-1 | S-1 (registration) | Aditxt, Inc. | 0001213900-24-004519 ↗ |
| 2024-01-26 | S-1/A | S-1/A (amendment) | Aditxt, Inc. | 0001213900-24-007068 ↗ |
| 2024-02-14 | S-1/A | S-1/A (amendment) | Aditxt, Inc. | 0001213900-24-013683 ↗ |
| 2024-05-14 | S-1/A | S-1/A (amendment) | Aditxt, Inc. | 0001213900-24-042539 ↗ |
| 2024-06-05 | S-1/A | S-1/A (amendment) | Aditxt, Inc. | 0001213900-24-050059 ↗ |
| 2024-06-13 | EFFECT | EFFECT (declared effective) | Aditxt, Inc. | 9999999995-24-001830 ↗ |
| 2024-08-06 | EFFECT | EFFECT (declared effective) | Aditxt, Inc. | 9999999995-24-002435 ↗ |
| 2024-09-11 | S-1/A | S-1/A (amendment) | Aditxt, Inc. | 0001213900-24-077771 ↗ |
| 2024-09-13 | EFFECT | EFFECT (declared effective) | Aditxt, Inc. | 9999999995-24-002845 ↗ |
| 2025-06-20 | S-1 | S-1 (registration) | Aditxt, Inc. | 0001213900-25-056288 ↗ |
| 2025-06-30 | EFFECT | EFFECT (declared effective) | Aditxt, Inc. | 9999999995-25-002100 ↗ |
| 2026-04-21 | EFFECT | EFFECT (declared effective) | Aditxt, Inc. | 9999999995-26-001275 ↗ |
Prospectus pages read 2
| Filed | Form | Read as | Range | Price | Shares | Proceeds | Listing | Underwriters | What was found | Document |
|---|---|---|---|---|---|---|---|---|---|---|
| 2020-06-25 | S-1/A | registration statement | $9.00 | 1,333,334 | $12,000,006 | Nasdaq ADTX | 1 | primary document; price sentence, shares headline, proceeds computed, underwriting table 1, cover names 1 | document ↗ | |
| 2020-07-01 | 424B4 | final prospectus | $9.00 | 1,226,668 | $11,040,012 | Nasdaq ADTX | 5 | primary document; price sentence, shares headline, proceeds table, underwriting table 3, cover names 4 | document ↗ |
Officers, directors and large holders Forms 3, 4 and 5
| Insider | Role | Title | Filings | Years | On this site |
|---|---|---|---|---|---|
| Albanna Amro A. | Director,Officer; Officer | Chief Executive Officer; CHIEF EXECUTIVE OFFICER | 8 | 2020–2023 | |
| ANTHONY LAURA E | Director | 4 | 2020–2021 | ||
| Brady Brian Michael | Director | 6 | 2020–2025 | ||
| Pankovcin Corinne | Officer | CCO; CHIEF FINANCIAL OFFICER; Chief M&A Officer | 7 | 2020–2025 | |
| Shabahang Shahrokh | Director,Officer; Officer | Chief Innovation Officer; CHIEF INNOVATION OFFICER | 8 | 2020–2023 | |
| Kiaie Namvar | Director | 5 | 2020–2021 | ||
| Albanna Rowena | Officer | Chief Operating Officer; CHIEF OPERATING OFFICER | 8 | 2020–2023 | |
| McLeod Rosland Fisher | Director | 1 | 2020 | ||
| Runge Jeffrey W. | Director | 7 | 2020–2023 | ||
| Farley Thomas J | Officer | Chief Financial Officer; PRINCIPAL ACCOUNTING OFFICER | 4 | 2021–2023 | |
| Chung Lauren | Director | 2 | 2021 | ||
| Shatzkes Matthew | Officer | Chief Legal Officer and GC | 1 | 2022 | |
| BNP PARIBAS SECURITIES CORP | Other; TenPercentOwner | 2 | 2023 | ||
| Nelson Charles Athle | Director | 2 | 2023 | ||
| HRT FINANCIAL LP | TenPercentOwner | 15 | 2024–2026 | ||
| PELLETIER SAUNDRA L | Director | 1 | 2025 | ||
| Hermina Sylvia | Director | 1 | 2025 | ||
| Porcelli Christopher Jon | Officer | General Counsel, CPO & CS | 1 | 2025 | |
| Gong Sandie | TenPercentOwner | 2 | 2026 | ||
| Xu Devon Xin | TenPercentOwner | 2 | 2026 | ||
| BANK OF AMERICA CORP /DE/ | TenPercentOwner | 2 | 2026 | ||
| BANK OF AMERICA NA | TenPercentOwner | 2 | 2026 | ||
| BOFA SECURITIES, INC. | TenPercentOwner | 2 | 2026 | ||
| DRW Securities, LLC | TenPercentOwner | 2 | 2026 | ||
| Takeover Time 2026 LLC | TenPercentOwner | 2 | 2026 | ||
| Tai Wey Ann | TenPercentOwner | 2 | 2026 |
Everyone who filed an insider report for this company, from the SEC’s Insider Transactions Data Sets (2006 on). Person pages are matched by name and state only.
Private offerings before or after (Form D)
| First filed | Issuer | Industry | Offering | Sold | Investors | Filings |
|---|---|---|---|---|---|---|
| 2024-01-23 | Aditxt, Inc. | Biotechnology | $6,000,000 | $6,000,000 | 1 | 1 |
| 2023-09-20 | Aditxt, Inc. | Biotechnology | $10,000,000 | $10,000,000 | 1 | 1 |
| 2022-08-17 | Aditxt, Inc. | Biotechnology | $2,200,000 | $2,033,333 | 6 | 1 |
| 2021-01-26 | Aditx Therapeutics, Inc. | Biotechnology | $6,000,000 | $6,000,000 | 1 | 1 |
| 2018-12-26 | ADiTx Therapeutics, Inc. | Biotechnology | $2,000,000 | $109,800 | 4 | 1 |
| 2018-03-29 | ADiTx Therapeutics, Inc. | Biotechnology | $2,000,000 | $262,500 | 8 | 1 |
Data: SEC EDGAR. The quarterly full index (every S-1, S-1/A, F-1 and F-1/A since 1993, with the pricing prospectus, notice of effectiveness and withdrawal request of each registrant) and the company submissions data (SIC, state of incorporation, address, EIN, tickers, former names). Company details are what EDGAR holds today, not at the time of the filing.
Also on this site Fuzzy
| Record | Name as filed | Where | Dataset | Matched by |
|---|---|---|---|---|
| Form D issuer | Aditxt, Inc. | VA | Form D private offerings | CIK (EXACT) |
| SEC filer | Aditxt, Inc. | SEC filers (EDGAR) | CIK (EXACT) | |
| Business registration | Aditxt, Inc. | State business registries | name and state | |
| Lobbying client | ADITXT INC. | Federal lobbying (LDA) | name and state |
Matched by an identifier (EIN, CIK, CRD), by name and state or city, or by street address; a shared name or address is not proof of the same person or organization. Every link says how it was made; how the cross-referencing works.
Others with the same interests
SIC industry Pharmaceutical Preparations, VA first:
- Osteologix, Inc. VA
- NEW RIVER PHARMACEUTICALS INC VA
- Quoin Pharmaceuticals Ltd. VA
- Landos Biopharma, Inc. VA
- Retension Pharmaceuticals, Inc. VA
- NovaCardia Inc CA
- MyoKardia, Inc. CA
- Bioquest Corp CA
- Regen BioPharma Inc CA
- Catalent, Inc. NJ
In other datasets, the same topic (Health) in VA:
- Nonprofit: ABSTINENCE EDUCATION OF VIRGINIA (Nonprofits (IRS Form 990))
Interests: Pharmaceutical Preparations · Health